Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients

REFERENCES

• Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994; 32: 39–47.
   PubMed Web of Science ®Google Scholar
• Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593–600.
   PubMed Web of Science ®Google Scholar
• Niskanen E, Blomqvist C, Franssila K, et al. Predictive value of c-erbB-2, p53 cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76(7): 917 —22.
   PubMed Web of Science ®Google Scholar
• Aas T, B6rresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811–4.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Dunnington G, Uzieli B, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39: 1059–68.
   PubMed Web of Science ®Google Scholar
• Bottini A, Berruti A, Bersiga A, et al. p53 but not bc1-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751–8.
   PubMed Web of Science ®Google Scholar
• Chevillard S, Lebeau J, Pouillart P, et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 1997; 3: 2471–8.
   PubMed Web of Science ®Google Scholar
• Elledge RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, metho-trexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87: 1254–6.
   PubMed Web of Science ®Google Scholar
• Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470–9.
   PubMed Web of Science ®Google Scholar
• Tetu B, Brisson J, Plante V, et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998; 11: 823–30.
   PubMed Web of Science ®Google Scholar
• Stal O, Stenmark Askmalm M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995; 34: 767–70.
   Google Scholar
• Dublin EA, Miles DW, Rubens RD, et al. p53 immunohisto-chemical staining and survival after adjuvant chemotherapy for breast cancer. Int J Cancer (Pred Oncol) 1997; 74: 605–8.
   PubMed Web of Science ®Google Scholar
• Berns EMJJ, Foekens JA, Vossen R, et al. Complete sequ-encing of TP53 predicts poor response to systemic the-rapy of advanced breast cancer. Cancer Res 2000; 60: 2155–62.
   PubMed Web of Science ®Google Scholar
• Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras, p21 p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72: 1259–66.
   PubMed Web of Science ®Google Scholar
• Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52: 79–98.
   PubMed Web of Science ®Google Scholar
• Berry DA, Muss HB, Thor AD, et al. Her-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18: 3471–9.
   PubMed Web of Science ®Google Scholar
• Knoop AS, Mentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19: 3376–84.
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Venoroni S, Benini E, et al. Expression of p53, Glutathione S-Transferase-n, and Bc1-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997; 89: 639–45.
   PubMed Web of Science ®Google Scholar
• Jansson T, Ingands M, Sjögren S, et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995; 13: 2745–51.
   Google Scholar
• Degeorges A, de Roquancourt A, Extra JM, et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 1998; 47: 47–55.
   PubMed Web of Science ®Google Scholar
• Elkhuizen PHM, Voogd AC, Lambert CJM, et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999; 45: 73–83.
   PubMed Web of Science ®Google Scholar
• Jager JJ, Jansen RL, Arends JW, et al. Anti-apoptotic phenotype is associated with decreased locoregional recur-rence rate in breast cancer. Anticancer Res 2000; 20(2B): 1269–75.
   Google Scholar
• Zellars RC, Hilsenbeck SG, Clark GM, et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 2000; 18: 1906–13.
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys 1989; 16: 629–39.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Non parametric estimation from incom-plete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Sjogren S, Ingands M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173–82.
   PubMed Web of Science ®Google Scholar
• Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumourigenesis. Mol Cell Biol 1990; 10(12): 6565–77.
   Google Scholar
• Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm2 interaction domains. Mol Cell Biol 1993; 13: 4107–14.
   PubMed Web of Science ®Google Scholar
• Fritsche M, Haessler C, Brandner. Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307–18.
   Google Scholar
• Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53: 2212–6.
   PubMed Web of Science ®Google Scholar
• Moll UM, Ostermeyer AG, Ahomadegebe JC, Mathieu MC, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage. Hum Pathol 1995; 26: 1293–301.
   Google Scholar
• Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996; 74: 555–61.
   PubMed Web of Science ®Google Scholar
• Andersen TI, Holm R, Nesland JM, et al. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 540–8.
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Thorgilsson B, Bjömsson J, et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995; 11: 1856–61.
   Google Scholar
• Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992; 11: 121–39.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks R, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–67.
   PubMed Web of Science ®Google Scholar
• Malcomson RDG, Oren M, Harrison DJ. p53-independent death and p53-induced protection against apoptosis in fibro-blasts treated with chemotherapeutic drugs. Br J Cancer 1995; 72: 952–7.
   Google Scholar
• Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–6.
   Google Scholar
• Brown JM, Wouters BG. Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391–9.
   PubMed Web of Science ®Google Scholar
• Almasan A, Yin Y, Kelly RE, et al. Deficiency of retinoblas-toma protein leads to inappropriate S-phase entry, activation of E2F-responive genes, and apoptosis. Proc Natl Acad Sci 1995; 92: 5436–40.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Kaelin WG. P53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001; 12: 337–49.
   PubMedGoogle Scholar
• Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001; 276: 11310–6.
   PubMed Web of Science ®Google Scholar
• Geisler S, Lönning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression of the response to treat-ment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505–12.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Rutqvist LE, Mattson A, et al. Ade-quate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995; 13: 2869–78.
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337: 949–55.
   PubMed Web of Science ®Google Scholar
• Ade11 G, Sun XF, Stal O, et al. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999; 51: 169–74.
   Google Scholar
• Elledge RM, Green S, Howes L, et al. bc1-2, p53 and response to tamoxifen in estrogen receptor positive metastatic breast cancer: a Southwest Oncology Group Study. J Clin Oncol 1997; 15: 1916–22.
   PubMed Web of Science ®Google Scholar
• Berns EMJJ, Klijn JGM, van Putten WLJ, et al. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 1998; 16: 121 —7.
   PubMed Web of Science ®Google Scholar